Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-27, Stock:NVS, The news for the past five days is as follows:
2019-08-20: NEWS1: Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS).NEWS2: INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS3: INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS).
2019-08-21: NEWS1: David Rolfe Adds 4 Stocks to Portfolio in 2nd Quarter.NEWS2: Teva Launches Generic Version of Mylan's EpiPen for KIds.NEWS3: Teva Launches Generic Version of Mylan's EpiPen for KIds.NEWS4: ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS5: Teva Launches Generic Version of Mylan's EpiPen for KIds.NEWS6: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS).
2019-08-22: NEWS1: Novo Nordisk's Fiasp Gets EC Approval for Label Expansion.NEWS2: Novo Nordisk's Fiasp Gets EC Approval for Label Expansion.NEWS3: Novo Nordisk's Fiasp Gets EC Approval for Label Expansion.
2019-08-23: NEWS1: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 26, 2019.NEWS2: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 26, 2019.
2019-08-26: NEWS1: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS2: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS3: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.

Answer: Rise